세계의 의약품 레퍼런스 앱 시장 - 규모, 점유율, 동향 분석 보고서 : 용도별, 가격 모델별, 디바이스별, 최종 용도별, 지역별 부문 예측(2025-2033년)

Drug Reference Apps Market Summary

The global drug reference apps market size was estimated at USD 1.30 billion in 2024 and is projected to reach USD 2.84 billion by 2033, growing at a CAGR of 9.17% from 2025 to 2033. Increasing adoption of reminders & adherence features among chronic disease patients is anticipated to boost market growth.

According to a JMIR Publications article published in April 2025, a systematic review analyzed nine studies involving 1,023 patients with chronic kidney disease (CKD) and found that 5 out of the nine mobile applications assessed demonstrated a statistically significant positive impact on medication adherence.

These apps employed features such as automated reminders, patient education modules, gamification elements, and medication monitoring tools. This evidence underscores the growing influence of (DRA) in enhancing adherence, supporting safer medication management, and strengthening its role as an essential tool in digital healthcare for chronic disease patients.

Rising clinical use of smartphones and apps for drug reference drives the growth of the market. According to an NCBI article published in March 2023, a review of smartphone and mobile app use among physicians found that in many settings, doctors routinely use their phones not just for communication or medical education but also to access drug compendia and clinical decision tools.

Healthcare is undergoing a rapid digital transformation, shifting from paper-based systems to fully integrated digital platforms such as Electronic Health Records (EHRs), Electronic Medical Records (EMRs), and Clinical Decision Support Systems (CDSS). This transformation enables healthcare providers to access critical patient information in real time. Drug reference apps are increasingly being embedded within these digital systems, allowing clinicians to instantly access up-to-date information on drug interactions, dosing guidelines, contraindications, and side effects. For instance, hospitals integrating apps such as Micromedex or Lexicomp into their EHR systems enable physicians and pharmacists to access drug data directly while reviewing a patient's medical record, significantly improving workflow efficiency and reducing errors. This trend is impactful in large hospitals and multi-specialty clinics, where rapid access to accurate drug information is crucial for patient safety and care quality.

Furthermore, patient safety is a factor driving the adoption of drug reference apps. Medication errors remain one of the leading causes of preventable hospital admissions and adverse drug events worldwide. Drug reference apps provide real-time, evidence-based information to help clinicians avoid prescribing errors, such as incorrect dosing, contraindicated medications, or dangerous drug interactions. They offer alerts for potential adverse effects and provide detailed information on drug administration and patient-specific considerations. For instance, a physician prescribing multiple medications for a cardiac patient can use a reference app to check for drug-drug interactions and adjust prescriptions accordingly. By minimizing risks associated with medication errors, these apps play a critical role in improving clinical outcomes and enhancing overall patient safety.

Global Drug Reference Apps Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and analyze industry trends in each sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the drug reference apps market report based on application, pricing model, device, end use, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Information/Drug Data Base
• Drug Interactions
• Dosage Calculators
• Pill/Drug Identification
• Others
• Pricing Model Outlook (Revenue, USD Million, 2021 - 2033)
• Freemium (Free)
• Paid (Subscription)
• Device Outlook (Revenue, USD Million, 2021 - 2033)
• Smartphones
• Tablets
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Healthcare Professionals
• Patients
• Pharmacists
• Researchers and Educators
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Spain
  • Italy
  • France
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. Pricing Model outlook
  • 2.2.3. Device outlook
  • 2.2.4. End use mode outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Drug Reference Apps Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic diseases driving demand for medication management and drug information accessibility.
    • 3.2.1.2. Increasing smartphone and tablet adoption among healthcare professionals and patients, enabling wider app usage.
    • 3.2.1.3. Growing integration of drug reference apps with electronic health records (EHRs), telemedicine platforms, and clinical workflows.
    • 3.2.1.4. Technological advancements in AI and real-time updates enhancing app functionality
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Concerns over data security and privacy
    • 3.2.2.2. Limited internet connectivity and technological infrastructure
• 3.3. Drug Reference Apps: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis
• 3.4. Regulatory Framework
• 3.5. Pricing Analysis
• 3.6. Technology Landscape
• 3.7. Case Study Analysis
• 3.8. Key Evaluation Metrics for Drug Reference Apps Market
• 3.9. Consumer Behavior Analysis
  • 3.9.1. Demographic Analysis
  • 3.9.2. Consumer Trends & Preferences
• 3.10. Parameters Considered in Designing Drug Reference Apps
• 3.11. Futuristic Trends in Drug Reference Apps Industry

Chapter 4. Drug Reference Apps Market Segment Analysis, By Application, 2021 - 2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Application Market Share Analysis, 2024 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Drug Reference Apps Market, by Application, 2021 to 2033
• 4.5. Drug Information/Drug Data Base
  • 4.5.1. Drug information/drug database market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Drug Interactions
  • 4.6.1. Drug interactions market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.7. Dosage Calculators
  • 4.7.1. Dosage calculators market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.8. Pill/Drug Identification
  • 4.8.1. Pill/drug identification market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Drug Reference Apps Market Segment Analysis, By Pricing Model, 2021 - 2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. Pricing Model Market Share Analysis, 2024 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Drug Reference Apps Market, by Pricing Model, 2021 to 2033
• 5.5. Freemium (Free)
  • 5.5.1. Freemium (Free) market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.6. Paid (Subscription)
  • 5.6.1. Paid (Subscription) market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Drug Reference Apps Market Segment Analysis, By Device, 2021 - 2033 (USD Million)

• 6.1. Definition and Scope
• 6.2. Device Market Share Analysis, 2024 & 2033
• 6.3. Segment Dashboard
• 6.4. Global Drug Reference Apps Market, by Device, 2021 to 2033
• 6.5. Smartphones
  • 6.5.1. Smartphones market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.6. Tablets
  • 6.6.1. Tablets market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Drug Reference Apps Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

• 7.1. Definition and Scope
• 7.2. End Use Market Share Analysis, 2024 & 2033
• 7.3. Segment Dashboard
• 7.4. Global Drug Reference Apps Market, by End Use, 2021 to 2033
• 7.5. Healthcare Professionals
  • 7.5.1. Healthcare professionals market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.6. Patients
  • 7.6.1. Patients market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.7. Pharmacists
  • 7.7.1. Pharmacists market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.8. Researchers and Educators
  • 7.8.1. Researchers and educators market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.9. Others
  • 7.9.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Drug Reference Apps Market Segment Analysis, By Region, 2021 - 2033 (USD Million)

• 8.1. Regional Market Share Analysis, 2024 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Regional Market Snapshot
• 8.4. Drug Reference Apps Market Share by Region, 2024 & 2033:
• 8.5. North America
  • 8.5.1. North America drug reference apps market, 2021 - 2033 (USD Million)
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory Scenario
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. U.S. drug reference apps market, 2021 - 2033 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory Scenario
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Canada drug reference apps market, 2021 - 2033 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory Scenario
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Mexico drug reference apps market, 2021 - 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe drug reference apps market, 2021 - 2033 (USD Million)
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory Scenario
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. UK drug reference apps market, 2021 - 2033 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory Scenario
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Germany drug reference apps market, 2021 - 2033 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory Scenario
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. France drug reference apps market, 2021 - 2033 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory Scenario
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Italy drug reference apps market, 2021 - 2033 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory Scenario
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. Spain drug reference apps market, 2021 - 2033 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory Scenario
    • 8.6.7.3. Competitive Scenario
    • 8.6.7.4. Norway drug reference apps market, 2021 - 2033 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory Scenario
    • 8.6.8.3. Competitive Scenario
    • 8.6.8.4. Sweden drug reference apps market, 2021 - 2033 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory Scenario
    • 8.6.9.3. Competitive Scenario
    • 8.6.9.4. Denmark drug reference apps market, 2021 - 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory Scenario
    • 8.7.1.3. Competitive Scenario
    • 8.7.1.4. Japan drug reference apps market, 2021 - 2033 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory Scenario
    • 8.7.2.3. Competitive Scenario
    • 8.7.2.4. China drug reference apps market, 2021 - 2033 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory Scenario
    • 8.7.3.3. Competitive Scenario
    • 8.7.3.4. India drug reference apps market, 2021 - 2033 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory Scenario
    • 8.7.4.3. Competitive Scenario
    • 8.7.4.4. Australia drug reference apps market, 2021 - 2033 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory Scenario
    • 8.7.5.3. Competitive Scenario
    • 8.7.5.4. South Korea drug reference apps market, 2021 - 2033 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory Scenario
    • 8.7.6.3. Competitive Scenario
    • 8.7.6.4. Thailand drug reference apps market, 2021 - 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory Scenario
    • 8.8.1.3. Competitive Scenario
    • 8.8.1.4. Brazil drug reference apps market, 2021 - 2033 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory Scenario
    • 8.8.2.3. Competitive Scenario
    • 8.8.2.4. Argentina drug reference apps market, 2021 - 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory Scenario
    • 8.9.1.3. Competitive Scenario
    • 8.9.1.4. South Africa drug reference apps market, 2021 - 2033 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory Scenario
    • 8.9.2.3. Competitive Scenario
    • 8.9.2.4. Saudi Arabia drug reference apps market, 2021 - 2033 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory Scenario
    • 8.9.3.3. Competitive Scenario
    • 8.9.3.4. UAE drug reference apps market, 2021 - 2033 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory Scenario
    • 8.9.4.3. Competitive Scenario
    • 8.9.4.4. Kuwait drug reference apps market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Epocrates
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Medscape
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. UpToDate Lexidrug (formerly Lexicomp)
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Micromedex (Merative US L.P.)
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. PillPack
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Pill Identifier & Med Scanner
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Mango Health
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Drugs.com
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. MDCalc
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Medisafe
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. MyTherapy
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives